



ASCELIA PHARMA

Share ticker: ACE
Nasdaq Stockholm

www.ascelia.com

[!\[\]\(666e09182d4cd268646ea700ea60dcdf_img.jpg\) Follow us on LinkedIn](#)

ASCELIA PHARMA

ADVANCING ORPHAN ONCOLOGY

Capital Markets Day

Magnus Corfitzen, CEO

21 October 2020

FORWARD LOOKING STATEMENTS

This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the "Presentation"), relates to Ascelia Pharma AB (publ) (hereinafter, together with its subsidiaries, the "Company") is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person without the prior written consent of the Company. You should not rely upon it or use it to form the definitive basis for any decision, contract, commitment or action whatsoever, with respect to any transaction or otherwise.

The information included in this Presentation may contain certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words "believes", "expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. Neither the Company nor any of its affiliates, directors, employees or advisors provides any assurance that the assumptions underlying such forward-looking statements are free from errors nor do any of them accept any responsibility for the future accuracy of the opinions expressed in this Presentation or the actual occurrence of the forecasted developments. This Presentation speaks as of the applicable reporting date, and there may have been changes in matters which affect the Company subsequent to the date of this Presentation. Neither the issue nor delivery of this Presentation shall under any circumstance create any implication that the information contained herein is correct as of any time subsequent to the date hereof or that the affairs of the Company have not since changed, and the Company does not intend, and does not assume any obligation, to update or correct any information included in this Presentation.

Each person should make their own independent assessment of the merits of the Company and should consult their own professional advisors. By receiving this Presentation, you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own opinion of the potential future performance of the Company's business.

ASCELIA PHARMA – ADVANCING ORPHAN ONCOLOGY



IMPROVING THE LIFE FOR PEOPLE
WITH RARE ONCOLOGY-RELATED
CONDITIONS

CURRENT ASSETS

Mangoral

- Global Phase 3 development ongoing
- For liver MRI in subset of overall population (Orphan Drug)

Oncoral

- Novel irinotecan tablet ready for Phase 2
- Focus on gastric cancer; potential in other cancer types

CAPABILITIES


People & Partners

- Strong experienced team
- World class network of global KOLs and advisors
- Supply chain in place


Financial

- Fully financed to reach substantial value creating milestones
- Listed on NASDAQ

BUILDING ASCELIA PHARMA AND BUILDING VALUE



INCREASED MANGORAL ADDRESSABLE MARKET TO \$500-600M



SAME PATIENT GROUP

NEW REAL-WORLD PROCEDURE DATA

ADDITIONAL PAYER AND EXPERT INPUT

BRIGHT FUTURE AHEAD – CREATING VALUE




Complete Mangoral development



Mangoral commercialization



Oncoral Phase 2 plan and execution



Grow the company